Predictors Of Marketing Authorization Status Of Dipyrone Within A Country
Isabella De Avellar Ramos1 , 
Slobodan M. Jankovic2
1 Faculty of Medicine, University of Santo Amaro, São Paulo, Brazil
2 Department of Pharmacology and Toxicology, University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
Corresponding Author: Isabella de Avellar Ramos, undergraduate student. University of Santo Amaro, Medical Faculty, São Paulo, Brazil; E-mail: isabellaavellar@icloud.com; Phone: +55 18 99761-0278.
Pages: 13-19 / Published online: 20 August 2024
Cite this article: De Avellar Ramos I, Jankovic S. Predictors Of Marketing Authorization Status Of Dipyrone Within A Country. Sar Med J. 2024; 1(1): Online ahead of print. 
DOI: 10.70119/0005-24.
Original submission: 16 March 2024; Revised submission: 08 June 2024; Accepted: 12 July 2024
Abstract
Introduction. Although there are numerous data about increased risk of bone marrow toxicity with dipyrone when compared to other nonsteroid anti-infl ammatory drugs, it continues to be marketed in many countries. The aim of this study was to identify currently unknown putative predictors of dipyrone having marketing authorization in a country.
Methods. The study was designed as secondary research of a cross-sectional type. The data were collected from web pages of relevant international and national entities. The main outcome variable of the study was dipyrone marketing authorization status within a country. The data were analyzed by both uni- and multi-variate statistics, including logistic regression.
Results. The following factors showed signifi cant infl uence on marketing authorization status of dipyrone: Current Health Expenditure per capita (p = 0.02), Gross Domestic Product per capita (p = 0.02), Incarceration Rate (per 100.000 population) (p = 0.04), and overall Global Innovati-on Index (p = 0.04). However, after adjustment, the multivariate analysis showed that the most important predictor was Current Health Expenditure per capita (p = 0.01).
Conclusion. The use of medications already considered by many to be obsolete and even dan-gerous due to their low benefi ts/harm ratio seems related to the underdevelopment of a country. There is a need for further research into ways to help these countries make better choices about the use of potentially harmful drugs and other health technologies.
Keywords: dipyrone, bone marrow toxicity, marketing authorization, predictors.
